EA201390499A1 - Соединения, подходящие для ингибирования снк1 - Google Patents

Соединения, подходящие для ингибирования снк1

Info

Publication number
EA201390499A1
EA201390499A1 EA201390499A EA201390499A EA201390499A1 EA 201390499 A1 EA201390499 A1 EA 201390499A1 EA 201390499 A EA201390499 A EA 201390499A EA 201390499 A EA201390499 A EA 201390499A EA 201390499 A1 EA201390499 A1 EA 201390499A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chk1
inhibition
compounds suitable
cancer
treatment
Prior art date
Application number
EA201390499A
Other languages
English (en)
Other versions
EA022096B1 (ru
Inventor
Саджан Джосеф
Сусанта Самадждар
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201390499A1 publication Critical patent/EA201390499A1/ru
Publication of EA022096B1 publication Critical patent/EA022096B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В настоящем изобретении предложено аминопиразольное соединение или его фармацевтически приемлемая соль, которые ингибируют Chk1 и подходят для лечения рака.
EA201390499A 2010-11-08 2011-11-01 Соединения, подходящие для ингибирования chk1 EA022096B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41113710P 2010-11-08 2010-11-08
PCT/US2011/058692 WO2012064548A1 (en) 2010-11-08 2011-11-01 Compounds useful for inhibiting chk1

Publications (2)

Publication Number Publication Date
EA201390499A1 true EA201390499A1 (ru) 2013-08-30
EA022096B1 EA022096B1 (ru) 2015-10-30

Family

ID=45044707

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390499A EA022096B1 (ru) 2010-11-08 2011-11-01 Соединения, подходящие для ингибирования chk1

Country Status (22)

Country Link
US (1) US9067920B2 (ru)
EP (1) EP2638033B1 (ru)
JP (1) JP5792316B2 (ru)
KR (1) KR101533166B1 (ru)
CN (1) CN103180311B (ru)
AR (1) AR083575A1 (ru)
AU (1) AU2011326230B2 (ru)
BR (1) BR112013010009B1 (ru)
CA (1) CA2816944C (ru)
DK (1) DK2638033T3 (ru)
EA (1) EA022096B1 (ru)
ES (1) ES2541414T3 (ru)
HR (1) HRP20150530T1 (ru)
JO (1) JO3145B1 (ru)
ME (1) ME02119B (ru)
MX (1) MX2013005181A (ru)
PL (1) PL2638033T3 (ru)
PT (1) PT2638033E (ru)
RS (1) RS54012B1 (ru)
SI (1) SI2638033T1 (ru)
TW (1) TWI501956B (ru)
WO (1) WO2012064548A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
MX2023006364A (es) 2020-11-30 2023-06-13 Sumitomo Pharma Co Ltd Derivado de 5-heteroaril-1h-pirazol-3-amina.
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
JPWO2023120696A1 (ru) 2021-12-24 2023-06-29
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
EP1732920B1 (en) * 2004-01-05 2011-03-09 AstraZeneca AB Thiophene derivatives as chk 1 inhibitors
JP2008501698A (ja) 2004-06-04 2008-01-24 アリーナ ファーマシューティカルズ， インコーポレイテッド 代謝の調節因子としての置換アリールおよびヘテロアリール誘導体ならびにそれらに関連する疾患の予防および処置
EP1888561A1 (en) * 2005-05-05 2008-02-20 AstraZeneca AB Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
AU2006258101A1 (en) * 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1

Also Published As

Publication number Publication date
BR112013010009A2 (pt) 2020-09-29
JP2013541586A (ja) 2013-11-14
US20130190262A1 (en) 2013-07-25
ME02119B (me) 2015-10-20
EP2638033A1 (en) 2013-09-18
DK2638033T3 (en) 2015-04-27
KR20130099146A (ko) 2013-09-05
CN103180311B (zh) 2014-08-20
US9067920B2 (en) 2015-06-30
CN103180311A (zh) 2013-06-26
PT2638033E (pt) 2015-06-01
CA2816944C (en) 2015-12-22
AU2011326230A1 (en) 2013-05-09
BR112013010009B1 (pt) 2021-10-19
JP5792316B2 (ja) 2015-10-07
JO3145B1 (ar) 2017-09-20
MX2013005181A (es) 2013-10-17
EP2638033B1 (en) 2015-04-08
HRP20150530T1 (hr) 2015-06-19
ES2541414T3 (es) 2015-07-20
SI2638033T1 (sl) 2015-05-29
EA022096B1 (ru) 2015-10-30
WO2012064548A1 (en) 2012-05-18
CA2816944A1 (en) 2012-05-18
AU2011326230B2 (en) 2015-02-19
KR101533166B1 (ko) 2015-07-01
TW201305138A (zh) 2013-02-01
RS54012B1 (en) 2015-10-30
PL2638033T3 (pl) 2015-09-30
TWI501956B (zh) 2015-10-01
AR083575A1 (es) 2013-03-06

Similar Documents

Publication Publication Date Title
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201591509A1 (ru) Ингибиторы cdc7
UA111382C2 (uk) Інгібітори протеїнкінази
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
MX2016008688A (es) Compuestos terapéuticos inhibidores.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
EA201200651A1 (ru) Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек
PH12016502353A1 (en) Pharmaceutical composition
EA201492104A1 (ru) Ингибитор jak1/2
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201270728A1 (ru) Пуриновые соединения
EA201200823A1 (ru) Гетероциклические производные сульфонамидов
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
CY1116362T1 (el) Ενωσεις χρησιμες στην αναστολη της chk1

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM